Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.

Vugmeyster, Yulia; Locke, George; Helwig, Christoph; Rolfe, P Alexander; Dong, Jennifer Q; Venkatakrishnan, Karthik

Vugmeyster, Yulia; Locke, George; Helwig, Christoph; Rolfe, P Alexander; Dong, Jennifer Q; Venkatakrishnan, Karthik.

Affiliation

Vugmeyster Y; EMD Serono, Billerica, Massachusetts, USA.
Locke G; EMD Serono, Billerica, Massachusetts, USA.
Helwig C; The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Rolfe PA; EMD Serono, Billerica, Massachusetts, USA.
Dong JQ; EMD Serono, Billerica, Massachusetts, USA.
Venkatakrishnan K; EMD Serono, Billerica, Massachusetts, USA.

Clin Transl Sci ; 15(12): 2838-2843, 2022 12.

Article in En | MEDLINE | ID: mdl-36152313

Subject(s)

Cytochrome P-450 CYP3A; Recombinant Fusion Proteins; Humans; Cytochrome P-450 CYP3A/metabolism; Drug Interactions; Risk Assessment; RNA, Messenger/genetics; Transforming Growth Factor beta; Recombinant Fusion Proteins/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Cytochrome P-450 CYP3A Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Transl Sci Year: 2022 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google